Addus CEO: Moratorium Has Little To No Impact On Growth, Valuations

Why It Matters

The ruling leaves Addus free to pursue its acquisition‑driven expansion while competitors face growth constraints, reinforcing its market position and potentially boosting shareholder value.

Key Takeaways

• Addus focuses on M&A, not de novo home health growth
• CMS moratorium excludes personal care services, sparing Addus growth
• Potential acquisitions must meet 36‑month rule to proceed
• Compliance spending positions Addus favorably in payer negotiations
• Valuations expected sub‑double‑digit multiples, down from 11x

Pulse Analysis

The Centers for Medicare & Medicaid Services recently announced a moratorium that freezes new Medicare enrollments for home‑health and hospice providers. Designed to curb fraud, waste, and abuse, the policy applies only to those two segments, leaving personal care services untouched. Industry analysts have warned that the freeze could limit growth levers for many operators, but the impact varies widely depending on each company’s service mix and acquisition pipeline.

Addus HomeCare, which operates 263 locations across 24 states and serves roughly 62,750 patients, is positioned to sidestep the moratorium’s constraints. The company’s revenue is heavily weighted toward personal care services, a segment not covered by the enrollment freeze. CEO Dirk Allison emphasized that Addus’s growth has historically come from acquisitions and organic expansion rather than de novo home‑health launches. Recent deals, such as the $350 million Gentiva PCS acquisition and the recent HomeCourt purchase in Indiana, demonstrate the firm’s ability to deploy cash quickly via its line of credit. With several PCS targets in the pipeline, Addus can continue scaling while competitors grapple with regulatory limits.

Valuation dynamics are also shifting. The Gentiva transaction was priced at roughly an 11‑11.5× multiple, but Allison noted that current market conditions and the company’s lower stock price are pushing expected multiples into sub‑double‑digit territory. Addus’s robust compliance infrastructure, honed by spending millions annually on program integrity, may further enhance its appeal to payers and investors seeking low‑risk partners. As the moratorium persists, Addus’s strategic focus on PCS acquisitions and strong compliance posture could translate into sustained growth and improved shareholder returns.